Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524746 | 1.00 | GLA (0.43) | GLANPSR1TLR9CTRB1MDM2 | |
| SCHEMBL3994040 | 0.86 | MEN1 (0.50) | GLANPSR1 | |
| SCHEMBL5380212 | 0.86 | MEN1 (0.50) | GLANPSR1 | |
| SCHEMBL3990482 | 0.83 | GLA (0.44) | GLANPSR1 | |
| SCHEMBL5385235 | 0.83 | GLA (0.44) | GLANPSR1 | |
| SCHEMBL29097002 | 0.82 | PLA2G6 (0.43) | FASN | |
| SCHEMBL7417047 | 0.79 | GLA (0.66) | GLANPSR1TLR9CTRB1MDM2 | |
| SCHEMBL25966683 | 0.78 | CTRB1 (0.42) | GLANPSR1TLR9CTRB1ELANE | |
| SCHEMBL2252699 | 0.76 | NPSR1 (0.43) | NPSR1TSHR | |
| SCHEMBL13804959 | 0.76 | POLB (0.48) | GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217909-A | Polymerization method of 1, 3-dioxolan-4-one compounds | 华东理工大学 | 2023-06-06 | — | — | CN | disclosed |
| US-7807677-B2 | HIV protease inhibitors | MEDIVIR AB (SE) | 2010-10-05 | — | — | US | disclosed |
| EP-1851193-B1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080249102-A1 | Hiv Protease Inhibitors | MEDIVIR AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1851193-A1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084688-A1 | HIV protease inhibitors | MEDIVIR AB (SE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249102-A1 | Hiv Protease Inhibitors | SERPINB1, ANPEP, XPNPEP1 | GLA 447/4885NPSR1 1505/4885TLR9 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.